© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 4, 263-281,
February 19, 2003
© 2003 Oxford University Press
REVIEW |
Health-Related Quality-of-Life Measurement in Randomized Clinical Trials in Breast Cancer—Taking Stock
Affiliations of authors: P. J. Goodwin, Department of Medicine, Division of Clinical Epidemiology, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; J. T. Black, Department of Health Services, University of California at Los Angeles (UCLA) School of Public Health, Los Angeles; L. J. Bordeleau, Department of Medicine, Mount Sinai Hospital, University of Toronto; P. A. Ganz, UCLA Schools of Medicine and Public Health and the Jonsson Comprehensive Cancer Center.
Correspondence to: Pamela J. Goodwin, M.D., M.Sc., F.R.C.P.C., Mount Sinai Hospital, 1284-600 University Ave., Toronto, Ontario M5G 1X5, Canada (e-mail: pgoodwin{at}mtsinai.on.ca).
Measurement of health-related quality-of-life (HRQOL) in randomized clinical trials in breast cancer has become common. In this review, we take stock of the contribution that HRQOL measurement in breast cancer clinical trials makes to clinical decision making regarding selection of optimal treatment. A series of MEDLINE searches was conducted to identify all randomized trials in breast cancer that included self-reported HRQOL or psychosocial outcomes. A total of 256 citations were identified that included HRQOL or psychosocial outcomes in breast cancer patients, and 66 of these involved randomized clinical trials of treatment. These 66 reports of breast cancer clinical trials of treatment are discussed in this review. Forty-six of the trials evaluated biomedical interventions, and 20 evaluated psychosocial interventions. Among the biomedical trials, eight trials evaluated HRQOL in primary management of breast cancer, seven trials evaluated HRQOL in adjuvant therapy of breast cancer patients, 20 trials involved metastatic breast cancer, eight trials involved symptom control/supportive care, and three trials evaluated different approaches to investigation or follow-up of breast cancer patients. Among the psychosocial trials, 13 trials evaluated HRQOL in adjuvant therapy of breast cancer patients, and their partners or spouses, six trials involved metastatic breast cancer, and one trial focused on symptom control. We found that the contribution of HRQOL measurement to clinical decision making depended on the clinical setting. In primary management of breast cancer, where medical outcomes of several treatment options are equivalent, HRQOL measurement provided added information for clinical decision making beyond that of traditional medical outcomes. In trials in the adjuvant setting, HRQOL measurement did not influence clinical decision making. In metastatic disease, HRQOL outcomes provided little information beyond that obtained from traditional medical outcomes, including toxicity. In the symptom control/supportive care setting, results of HRQOL questionnaires targeting specific symptoms (e.g., emesis) guided treatment decisions. In psychosocial intervention trials, psychosocial and/or HRQOL measurements often provided the only outcome information; therefore, selection of instruments that captured attributes likely to be altered by the intervention was essential. Until results of ongoing trials in breast cancer are available, caution is recommended in initiating new HRQOL studies unless treatment equivalency is expected, or unless the HRQOL questions target unique or specific issues that can only be addressed through patient self-report, including outcomes of psychosocial interventions.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Parameswaran, A. McNair, K. N. L. Avery, R. G. Berrisford, S. A. Wajed, M. A. G. Sprangers, and J. M. Blazeby The Role of Health-Related Quality of Life Outcomes in Clinical Decision Making in Surgery for Esophageal Cancer: A Systematic Review Ann. Surg. Oncol., September 1, 2008; 15(9): 2372 - 2379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Hormes, L. A. Lytle, C. R. Gross, R. L. Ahmed, A. B. Troxel, and K. H. Schmitz The Body Image and Relationships Scale: Development and Validation of a Measure of Body Image in Female Breast Cancer Survivors J. Clin. Oncol., March 10, 2008; 26(8): 1269 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Joly, J. Vardy, M. Pintilie, and I. F. Tannock Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer Ann. Onc., December 1, 2007; 18(12): 1935 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Bardwell, L. Natarajan, J. E. Dimsdale, C. L. Rock, J. E. Mortimer, K. Hollenbach, and J. P. Pierce Objective Cancer-Related Variables Are Not Associated With Depressive Symptoms in Women Treated for Early-Stage Breast Cancer J. Clin. Oncol., June 1, 2006; 24(16): 2420 - 2427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Whelan and K. I. Pritchard Managing Patients on Endocrine Therapy: Focus on Quality-of-Life Issues Clin. Cancer Res., February 1, 2006; 12(3): 1056s - 1060s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Lieberman and B. A. Goldstein Self-help On-line: An Outcome Evaluation of Breast Cancer Bulletin Boards J Health Psychol, December 1, 2005; 10(6): 855 - 862. [Abstract] [PDF]
|
|
|
|
|
|
A. L. Stanton How and for Whom? Asking Questions About the Utility of Psychosocial Interventions for Individuals Diagnosed With Cancer J. Clin. Oncol., August 1, 2005; 23(22): 4818 - 4820. [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Stanton, C. A. Bernaards, and P. A. Ganz The BCPT Symptom Scales: A Measure of Physical Symptoms for Women Diagnosed With or at Risk for Breast Cancer J Natl Cancer Inst, March 16, 2005; 97(6): 448 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Buchanan, A. M. O'Mara, J. W. Kelaghan, and L. M. Minasian Quality-of-Life Assessment in the Symptom Management Trials of the National Cancer Institute-Supported Community Clinical Oncology Program J. Clin. Oncol., January 20, 2005; 23(3): 591 - 598. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lipscomb, M. S. Donaldson, N. K. Arora, M. L. Brown, S. B. Clauser, A. L. Potosky, B. B. Reeve, J. H. Rowland, C. F. Snyder, and S. H. Taplin Cancer Outcomes Research J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 178 - 197. [Full Text] [PDF]
|
|
|
|
|
|
K. L. Taylor, R. Shelby, E. Gelmann, and C. McGuire Quality of Life and Trial Adherence Among Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial J Natl Cancer Inst, July 21, 2004; 96(14): 1083 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Goodwin Reversible Ovarian Ablation or Chemotherapy: Are We Ready for Quality of Life to Guide Adjuvant Treatment Decisions in Breast Cancer? J. Clin. Oncol., December 15, 2003; 21(24): 4474 - 4475. [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. Chung and R. W. Carlson Goals and Objectives in the Management of Metastatic Breast Cancer Oncologist, December 1, 2003; 8(6): 514 - 520. [Abstract] [Full Text] [PDF]
|
|